Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
30 June 2003Website:
http://pluri-biotech.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 02 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
PLUR Latest News
HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri's subsidiary, Ever After Foods Ltd. (“Ever After Foods”), which offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. Ever After Foods is Pluri's majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator (2019), L.P. (“Tnuva”), and has exclusive licensing rights to use Pluri's technology and intellectual property to develop, manufacture and commercialize cultivated meat. The $10 million funding round will propel Ever After Foods' cost-advantageous and scalable technology platform, positioning it as a leading technology enabler.
HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced a strategic collaboration with Wilk Technologies Ltd. (TASE: WILK) (“Wilk Technologies” or “Wilk”), a developer of authentic, cell-cultured human and animal milk components. By combining Pluri's cutting-edge 3D cell-expansion technology with Wilk's expertise in developing cultured human breast and animal milk products, the strategic collaboration will use the components of breast milk to develop a unique medical food intended for the elderly on a commercial scale.
Pluri's business verticals leverage Company's world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries Pluri's business verticals leverage Company's world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries
What type of business is Pluri?
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
What sector is Pluri in?
Pluri is in the Healthcare sector
What industry is Pluri in?
Pluri is in the Biotechnology industry
What country is Pluri from?
Pluri is headquartered in Israel
When did Pluri go public?
Pluri initial public offering (IPO) was on 30 June 2003
What is Pluri website?
https://pluri-biotech.com/
Is Pluri in the S&P 500?
No, Pluri is not included in the S&P 500 index
Is Pluri in the NASDAQ 100?
No, Pluri is not included in the NASDAQ 100 index
Is Pluri in the Dow Jones?
No, Pluri is not included in the Dow Jones index
When does Pluri report earnings?
The next expected earnings date for Pluri is 13 November 2024